Essex Bio-Technology Limited reported the repurchase of 135,000 ordinary shares on 18 June 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange. The shares were bought on-market at prices ranging from HKD 2.63 to HKD 2.65, resulting in a volume-weighted average cost of HKD 2.6411 per share and an aggregate cash outlay of approximately HKD 0.36 million.

Following the transaction, the company’s outstanding issued share capital (excluding treasury shares) fell to 566.87 million shares from 567.01 million, representing a 0.02% reduction. All repurchased shares have been retained as treasury stock, leaving the total issued share count unchanged at 567.01 million.

The buyback forms part of a broader mandate approved by shareholders on 26 May 2026, which authorises Essex Bio-Tech to repurchase up to 56.70 million shares. To date, only 135,000 shares—or 0.02% of the approved limit—have been utilised, leaving capacity for an additional 56.57 million shares.

In line with Main Board Rule 10.06(3)(a), the company is restricted from issuing new shares or disposing of treasury shares until 18 July 2026. Management confirmed that the repurchase complied with all applicable listing rules and regulatory requirements.